ArticleHepatology communications2019
Article in Hepatology communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 35 citations in OpenAlex.
- Metabolic reprogramming in hepatic stellate cells: unveiling a novel therapeutic target for liver fibrosis.Frontiers in physiology · 2026Review
- Innate immune cell LXR-β deficiency exacerbates hepatic injury and fibrosis in murine models of primary sclerosing cholangitis.Liver research (Beijing, China) · 2025Article
- Cellular communication networks in fibrosis: Insights from the MASLD pig model.Hepatology communications · 2025Article
- Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Frontiers in physiology · 2025Review
- PNPLA3 I148 M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality.Journal of translational autoimmunity · 2024Article
- Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.Journal of gastroenterology and hepatology · 2023Review
- An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.Journal of hepatology · 2023Review
- PNPLA3-I148M Variant Promotes the Progression of Liver Fibrosis by Inducing Mitochondrial Dysfunction.International journal of molecular sciences · 2023Article
- Role of the Hippo pathway in liver regeneration and repair: recent advances.Inflammation and regeneration · 2022Review
- Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.Seminars in liver disease · 2022Review
- KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells.Journal of lipid research · 2022Article
- Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.Hepatology (Baltimore, Md.) · 2021Article
- Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer.Cancers · 2021Review
- Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.Hepatology international · 2021Article
- Liver X receptors and liver physiology.Biochimica et biophysica acta. Molecular basis of disease · 2021Review
- The Ameliorative Effects of Fucoidan in Thioacetaide-Induced Liver Injury in Mice.Molecules (Basel, Switzerland) · 2021Article
- Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice.International journal of molecular sciences · 2021Article
- PNPLA3 downregulation exacerbates the fibrotic response in human hepatic stellate cells.PloS one · 2021Article
- 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.Cancer letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The patatin-like phospholipase domain-containing protein 3 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.